Hospital de Câncer de Barretos, Barretos, SP, Brazil.
Clinics (Sao Paulo). 2011;66(11):1901-9. doi: 10.1590/s1807-59322011001100009.
The proper nodal staging of non-small cell lung cancer is important for choosing the best treatment modality. Although computed tomography remains the first-line imaging test for the primary staging of lung cancer, its limitations for mediastinum nodal staging are well known. The aim of this study is to evaluate the accuracy of hybrid single-photon emission computed tomography and computed tomography using 99mTc-sestamibi in the nodal staging of patients with non-small cell lung cancer and to identify potential candidates for surgical treatment.
Prospective data were collected for 41 patients from December 2006 to February 2009. The patients underwent chest computed tomography and single-photon emission computed tomography/computed tomography examinations with 99mTc-sestamibi within a 30-day time period before surgery. Single-photon emission computed tomography/computed tomography was considered positive when there was focal uptake of sestamibi in the mediastinum, and computed tomography scan when there was lymph nodes larger than 10 mm in short axis. The results of single-photon emission computed tomography and computed tomography were correlated with pathology findings after surgery.
Single-photon emission computed tomography/computed tomography correctly identified six out of 19 cases involving hilar lymph nodes and one out of seven cases involving nodal metastases in the mediastinum. The sensitivity, specificity, positive predictive value, and negative predictive value for 99mTc-sestamibi single-photon emission computed tomography/computed tomography in the hilum assessment were 31.6%, 95.5%, 85.7%, and 61.8%, respectively. The same values for the mediastinum were 14.3%, 97.1%, 50%, and 84.6%, respectively. For the hilar and mediastinal lymph nodes, chest tomography showed sensitivity values of 47.4% and 57.1%, specificity values of 95.5% and 91.2%, positive predictive values of 90% and 57.1% and negative predictive values of 67.7% and 91.2%, respectively.
Single-photon emission computed tomography/computed tomography with 99mTc-sestamibi showed very low sensitivity and accuracy for the nodal staging of patients with non-small cell lung cancer, despite its high level of specificity. In addition, the performance of single-photon emission computed tomography/computed tomography added no relevant information compared to computed tomography that would justify its use in the routine preoperative staging of non-small cell lung carcinoma.
准确的非小细胞肺癌淋巴结分期对于选择最佳治疗方案非常重要。虽然计算机断层扫描(CT)仍然是肺癌初步分期的一线影像学检查方法,但它在纵隔淋巴结分期方面的局限性是众所周知的。本研究旨在评估 99mTc-甲氧基异丁基异腈单光子发射计算机断层扫描/CT(SPECT/CT)在非小细胞肺癌患者淋巴结分期中的准确性,并确定潜在的手术治疗候选者。
2006 年 12 月至 2009 年 2 月,前瞻性地收集了 41 例患者的数据。这些患者在术前 30 天内接受了胸部 CT 和 99mTc-甲氧基异丁基异腈 SPECT/CT 检查。当纵隔有锝-99m 甲氧基异丁基异腈摄取焦点时,SPECT/CT 被认为是阳性的;当短轴淋巴结大于 10mm 时,CT 扫描为阳性。SPECT/CT 的结果与手术后的病理发现相关联。
SPECT/CT 正确识别了 19 例肺门淋巴结受累中的 6 例和 7 例纵隔淋巴结转移中的 1 例。99mTc-甲氧基异丁基异腈 SPECT/CT 在肺门评估中的敏感性、特异性、阳性预测值和阴性预测值分别为 31.6%、95.5%、85.7%和 61.8%。纵隔的相应值分别为 14.3%、97.1%、50%和 84.6%。对于肺门和纵隔淋巴结,胸部 CT 的敏感性值分别为 47.4%和 57.1%,特异性值分别为 95.5%和 91.2%,阳性预测值分别为 90%和 57.1%,阴性预测值分别为 67.7%和 91.2%。
尽管 99mTc-甲氧基异丁基异腈 SPECT/CT 具有很高的特异性,但对于非小细胞肺癌患者的淋巴结分期,其敏感性和准确性都非常低。此外,与 CT 相比,SPECT/CT 的性能并未提供任何有价值的信息,无法证明其在非小细胞肺癌常规术前分期中的应用是合理的。